Nasometin (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors in the nasal mucosa, altering gene transcription to suppress pro‑inflammatory cytokines and inhibit the migration of inflammatory cells. This anti‑inflammatory action reduces swelling, mucus production, and the overall allergic response within the nasal passages.

The dosing regimen for Nasometin is individualized by a prescriber based on the patient’s age, severity of symptoms, and clinical response. Healthcare professionals determine the number of sprays per nostril and the frequency of administration, typically ranging from once to twice daily.

Safety of Nasometin in pregnancy or while breastfeeding has not been definitively established. Women who are pregnant, planning to become pregnant, or nursing should discuss potential risks and benefits with their healthcare provider before starting treatment.

To order Nasometin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Nasometin (mometasone furoate) is a high‑potency nasal corticosteroid with a favorable safety profile when used at recommended doses. Compared with lower‑potency agents such as fluticasone propionate, mometasone may provide comparable symptom control with once‑daily dosing, but individual response and tolerability can vary.

Nasometin should be stored at room temperature, below 25 °C, in its original packaging. Keep the spray bottle tightly closed, protect it from moisture and direct sunlight, and avoid freezing to maintain product stability.

Nasometin is administered as a nasal spray. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and spray the prescribed number of sprays while breathing in gently. The process is repeated in the other nostril if directed by the prescriber.

Serious risks, though rare, include nasal septal perforation, severe or persistent nosebleeds, adrenal suppression with prolonged high‑dose use, and hypersensitivity reactions such as angioedema. Patients should seek medical attention promptly if they experience any of these adverse events.

Nasometin should be avoided in individuals with a known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated in patients with untreated bacterial, fungal, or viral infections of the nasal passages until the infection has been appropriately managed.